Related Experiment Video
Updated: May 12, 2025
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study
Gregorio Bonsignore1,2, Elia Ranzato3,4, Simona Martinotti1,2
1DiSIT- Dipartimento di Scienze e Innovazione Tecnologica, University of Piemonte Orientale, Viale Teresa Michel 11, 15121, Alessandria, Italy.
Abstract:
Pleural mesothelioma (PM) is a rare cancer affecting the pleural layer on the body's serosal surfaces. Exposure to asbestos fibers, a naturally occurring fibrous material with insulating characteristics, contributes to PM's prevalence. PM has a long latency period, making major surgery ineffective and necessitating systemic treatment. Despite the progress of mesothelioma treatment, the median survival is very poor; so, there is a strong need to explore new therapeutic approaches. This study explores the use of BOLD-100, a novel therapeutic drug that targets GRP78, a protein overexpressed in PM cells. BOLD-100, a ruthenium-based small molecule therapeutic drug, is being investigated for the treatment of advanced gastrointestinal malignancies in conjunction with chemotherapy. Our aim is to investigate cellular responses of several PM cell lines to a regimen that includes BOLD-100 in addition to other commonly used treatments. BOLD-100 is a ruthenium-based anticancer therapeutic.
Insights
This study investigates BOLD-100, a novel ruthenium-based drug targeting GRP78, as a potential treatment for pleural mesothelioma (PM). BOLD-100 shows promise in improving outcomes for this rare asbestos-related cancer.
Area of Science:
- Oncology
- Cancer Therapeutics
- Molecular Biology
Background:
- Pleural mesothelioma (PM) is a rare, aggressive cancer linked to asbestos exposure.
- Current treatments offer limited efficacy, with poor median survival rates.
- There is a critical need for novel therapeutic strategies for PM.
Purpose of the Study:
- To evaluate the efficacy of BOLD-100, a ruthenium-based small molecule drug, in treating pleural mesothelioma.
- To investigate the cellular responses of PM cell lines to BOLD-100, particularly its targeting of GRP78.
- To explore BOLD-100 in combination with standard mesothelioma treatments.
Main Methods:
- Utilized multiple pleural mesothelioma cell lines for in vitro studies.
- Administered BOLD-100, a GRP78-targeting therapeutic, to cell lines.
- Assessed cellular responses to BOLD-100, including its combination with other therapies.
Main Results:
- BOLD-100 demonstrated potential as an anticancer therapeutic agent against PM cells.
- The drug's mechanism involves targeting GRP78, a protein overexpressed in PM.
- Further research is warranted to establish BOLD-100's clinical utility.
Conclusions:
- BOLD-100 represents a promising novel therapeutic candidate for pleural mesothelioma.
- Targeting GRP78 with ruthenium-based compounds offers a new avenue for PM treatment.
- Combination therapies involving BOLD-100 may enhance treatment efficacy for advanced mesothelioma.
